New York – September 9, 2015 – New manufacturing strategies, emerging analytical tools and formulation strategies, and techniques to accelerate the transition from biologics discovery to IND and beyond are just three topics that will be addressed in the conference tracks at the 12th Annual BioProcess International (BPI) Conference & Exposition. IBC Life Sciences USA, an Informa company, is hosting the event October 26-29 in Boston and has designed BPI 2015 to bring forward new ideas, demystify technologies, and foster partnerships between attendees and exhibitors.
A total of six conference tracks are available to conference attendees. Each track will be comprised of presentations from highly regarded industry leaders to provide scientists and engineers with invaluable knowledge, so they can more effectively advance drug candidates closer to approval.
“By offering six comprehensive tracks as part of the registration fee, we are allowing attendees to specialize in topics of interest and importance to them. Further, we are creating an environment to expand horizons across a variety of disciplines so scientists and engineers can have a personalized, curated content experience,” said Barry Walsh, BPI Conference Director.
Manufacturing Strategies
Some of the most respected biomanufacturing experts will share their strategies to maximize efficiencies and lower costs across the manufacturing network in this track. Pall Life Sciences will sponsor a series of presentations that discuss Practical Experiences from Single-use Technology Implementation as part of the track. Additionally, a case study entitled “ADC Production: Integration of the Conjugation Step in a Standard Protein Plant Using Closed Systems” will be presented by Berthold Boedeker, Ph.D., Chief Scientist, Global Biologics, Biotech Development, Bayer Pharma, AG.
Analytical, Formulation & Quality
In this track, industry thought leaders will keep attendees up to date on emerging analytical tools and formulation strategies for mAb, non-mAb, and next-generation biotherapeutics. The impact of increasing quality expectations to optimize analytical and formulation strategies to reduce quality risks across the product lifecycle will be discussed, as well. Included in the track will be a case study by Greg W. Adams, Ph.D., Director Analytical Development, Fujifilm Diosynth Biotechniques. The study is entitled “Application of Analytical Techniques for Product Quality Driven Process Development and Routine cGMP Manufacturing.”
Early Stage Biologics & Companies
Attendees of this track will learn methods to accelerate the transition from biologics discovery to IND and beyond by implementing key strategies and critical development activities. Market experts will help guide attendees through the steps that can help reduce risk, develop timelines and costs, and maximize the chance of new product success. Among the case studies presented will be “De-risking Timeline Acceleration and Improving Product Quality: A Case Study of Integrating Lead Selection and Early Development Activities” given by Susan Dana Jones, Ph.D., Vice President and Principal Consultant, BioProcess Technology Consultants.
To optimize the experience, attendees can consolidate tracks of interest for shared sessions so they can cross-fertilize ideas with other bioprocessing professionals from different disciplines. In addition to the conference tracks, scientists and engineers who attend BPI 2015 can listen to five keynote addresses and more than 160 prominent speakers, as well as view over 100 peer-submitted scientific posters. They will also have valuable networking opportunities, including Ask the Regulators Open Forum, 15 Bioprocessing Problem-Solving Moderated Discussions, and Town Hall Forums.
To learn more about BPI or to register, visit www.IBCLifeSciences.com/BPI.
About BPI Conference & Exposition
BPI, an IBC USA conference and exposition, is the largest bioprocessing event that brings attendees new ideas, helps advance and explain technologies, and fosters partnerships in highly engaging formats to move drug candidates closer to approval. It delivers the most comprehensive science, the most innovative technologies, and the best partners enabling scientists and engineers to reach new heights of clinical and commercial success. IBC USA is an Informa company. To learn more, visit www.IBCLifeSciences.com/BPI.
###
For more information, contact:
Howard Choi
Marketing Manager, Life Sciences Group
508.614.1494
hchoi@ibcusa.com
Phylicia Clifton
Marketing Communications Manager
646.895.7340
pclifton@iirusa.com
